About Us
Katya Tsaioun, Ph.D.
Bruno Villoutreix, Ph.D.
Bruno Villoutreix, Ph.D.
20+ years experience in academia and Boston area biotech industry; successful entrepreneur (founded Apredica, an ADME-Tox CRO in 2006, exit to Cyprotex, PLC (now Evotec)); expertise in ADME-Tox and mechanistic strategies for hit-to-lead, lead optimization and de-risking drug-discovery programs.
Bruno Villoutreix, Ph.D.
Bruno Villoutreix, Ph.D.
Bruno Villoutreix, Ph.D.
25+ years international experience at the interface between molecular medicine (cancer, complement system, blood coagulation), structural bioinformatics and chemoinformatics both in the private and academic sectors in USA, Finland, Sweden, Bulgaria, France. Research director at INSERM U1141, Hospital Robert Debré, Paris, France. Biomolecular modeling, drug design, ADME-Tox prediction.
Lana Gladstein, J.D.
Bruno Villoutreix, Ph.D.
Yosef landesman, Ph.D.T
Chief Legal Officer, Arranta Bio; previously EVP and General Counsel of Brammer Bio (exit to Thermo Fisher in 2019); formerly partner at Troutman Pepper, and partner at Nutter, Boston, MA
Yosef landesman, Ph.D.T
Yosef landesman, Ph.D.T
Yosef landesman, Ph.D.T
Dr. Landesman brings 20 years of experience in drug discovery, development, and regulatory approval in the biotech and pharmaceutical industries. He served as Chief Scientific Officer at hC Bioscience focusing on advancing tRNA therapeutics. Prior to this, Dr. Landesman assumed the role of Senior Vice President of Research and Translation
Dr. Landesman brings 20 years of experience in drug discovery, development, and regulatory approval in the biotech and pharmaceutical industries. He served as Chief Scientific Officer at hC Bioscience focusing on advancing tRNA therapeutics. Prior to this, Dr. Landesman assumed the role of Senior Vice President of Research and Translational Medicine at Karyopharm Therapeutics. His leadership was critical to advancing preclinical and clinical research, preclinical DMPK, translational medicine, bioinformatics, and Karyopharm’s Expanded Access Program. Dr. Landesman led the preclinical development of XPOVIO® (selinexor), which received three FDA approvals for the treatment of multiple myeloma and diffuse large B-cell lymphoma. He also initiated discovery and development of the Pak4/NAMPT dual inhibitor KPT-9274, which is currently in a Phase 1 clinical trial.
Before joining Karyopharm, Dr. Landesman worked at Alnylam Pharmaceuticals where he played a critical role in establishing the “RNAi Lead Development” department and contributed to the development of ONPATTRO® (patisiran). He began his career in industry as a scientist at GPC Biotech where he developed small molecule Cyclin Dependent Kinase inhibitors.
Dr. Landesman serves on the Data and Safety Monitoring Board of Advenchen Laboratories, LLC. He is a founder of the patient advisory group Cure Alveolar Soft Part Sarcoma International. His work has resulted in inventorship on 17 patents for proprietary therapeutics and treatment biomarkers. He received his PhD in Molecular Genetics and Virology from the Weizmann Institute of Science, and then completed postdoctoral training and became faculty in the neurobiology department at Harvard Medical School.
Usamah Kayyali, Ph.D.
Yosef landesman, Ph.D.T
Usamah Kayyali, Ph.D.
Dr. Usamah Kayyali previously conducted research over two decades in molecular and cell biology of disease at Harvard and Tufts Universities, which was funded by the NIH and other agencies. His lab demonstrated a role for p38 MAP kinase-MK2 activation in augmenting the vascular endothelium, and developed an MK2-activating peptide as a p
Dr. Usamah Kayyali previously conducted research over two decades in molecular and cell biology of disease at Harvard and Tufts Universities, which was funded by the NIH and other agencies. His lab demonstrated a role for p38 MAP kinase-MK2 activation in augmenting the vascular endothelium, and developed an MK2-activating peptide as a potential drug. He currently serves as Scientific Advisor for Akttyva.
Mark Tepper, Ph.D.
Yosef landesman, Ph.D.T
Usamah Kayyali, Ph.D.
Dr. Tepper has over 30 years of experience in the biotechnology and pharmaceutical industry. He has led drug discovery & development programs that span a wide range of therapeutic areas including Oncology, Immunology, Rheumatology, Endocrinology, Metabolic Diseases, CNS Diseases, Inflammation and Pain. In addition, he has founded multip
Dr. Tepper has over 30 years of experience in the biotechnology and pharmaceutical industry. He has led drug discovery & development programs that span a wide range of therapeutic areas including Oncology, Immunology, Rheumatology, Endocrinology, Metabolic Diseases, CNS Diseases, Inflammation and Pain. In addition, he has founded multiple companies based on novel technologies in the area of RNA interference, structure-based drug design, small molecule and protein therapeutics, biosensors, microfluidics and biomaterials. He has taken 2 of his companies public (RXii & CRBP) and sold one in a trade sale to KNSA.
Mario DiPaola, Ph.D.
Mario DiPaola, Ph.D.
Mario DiPaola, Ph.D.
Dr. Mario DiPaola is an experienced executive with a 25-year record in the biotechnology and pharmaceutical industries. He is the founder or co-founder of a number of companies, including Blue Stream Labs Inc., Oncovolution LLC, Therabene LLC and Higher-Order Technologies LLC. He is also the author of several patents and 50+ publications.